Formal Japan approval for Macugen and Graceptor
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfarehas confirmed the final approval for a large group of products includingPfizer's VEGF-antagonist Macugen (pegaptanib sodium) for age-related macular degeneration andAstellas's once-daily formulation of tacrolimus, Graceptor.